Although the underlying mechanism leading to ILD in patients receiving mTOR inhibitors is not fully clarified, dose-dependent toxicity, T cell-mediated delayed-type hypersensitivity reaction, and idiosyncratic cell-mediated autoimmune response have been suggested as potential mechanisms [10, 21, 25, 40, 51, 60]. The gene discussed is MTOR; the disease is interstitial lung disease.